PRCT · Procept Biorobotics Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $83.13M | - | $83.33M | $79.18M | $69.16M | - | $58.37M | $53.35M | $44.54M | - |
| Cost of Revenue | $29.18M | - | $29.32M | $27.44M | $25.00M | - | $21.46M | $21.87M | $19.50M | - |
| Gross Profit | $53.95M | - | $54.01M | $51.75M | $44.16M | - | $36.91M | $31.48M | $25.03M | - |
| R&D | $21.46M | - | $18.19M | $17.63M | $16.40M | - | $16.65M | $17.50M | $13.08M | - |
| SG&A | $65.09M | - | $59.01M | $56.30M | $55.20M | - | $42.69M | $40.81M | $39.60M | - |
| Total Operating Expenses | $86.55M | - | $77.20M | $73.94M | $71.60M | - | $59.34M | $58.31M | $52.68M | - |
| D&A | $1.74M | - | - | - | $1.48M | - | - | - | $1.18M | - |
| Operating Income | ($32.61M) | - | ($23.19M) | ($22.19M) | ($27.44M) | - | ($22.43M) | ($26.83M) | ($27.65M) | - |
| Interest Expense | $818.0K | - | $919.0K | $895.0K | $1.04M | - | $1.02M | $965.0K | $1.04M | - |
| Income Tax | ($47.0K) | - | - | - | - | - | - | - | - | - |
| Net Income | ($31.64M) | - | ($21.41M) | ($19.58M) | ($24.74M) | - | ($20.97M) | ($25.63M) | ($25.96M) | - |
| EPS - Basic | ($0.56) | - | ($0.38) | ($0.35) | ($0.45) | - | ($0.40) | ($0.50) | ($0.51) | - |
| EPS - Diluted | ($0.56) | - | ($0.38) | ($0.35) | ($0.45) | - | ($0.40) | ($0.50) | ($0.51) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $245.64M | $286.50M | $294.28M | $302.72M | $316.21M | $333.73M | $196.76M | $214.09M | $225.58M | $257.22M |
| Accounts Receivable | $96.39M | $83.53M | $84.50M | $80.82M | $79.27M | $83.50M | $69.05M | $58.92M | $56.08M | $48.38M |
| Inventory | $77.54M | $70.69M | $66.72M | $67.03M | $62.33M | $56.17M | $50.85M | $43.87M | $41.62M | $39.76M |
| Accounts Payable | $18.85M | $17.29M | $11.12M | $11.78M | $14.83M | $10.03M | $15.09M | $9.95M | $10.08M | $13.50M |
| Current Assets | $428.03M | $450.38M | $454.75M | $458.07M | $465.79M | $481.84M | $322.98M | $321.89M | $329.19M | $350.57M |
| Total Assets | $487.06M | $508.08M | $511.54M | $513.05M | $519.38M | $534.02M | $374.14M | $374.35M | $382.90M | $404.72M |
| Current Liabilities | $63.64M | $65.80M | $53.90M | $49.73M | $52.06M | $53.13M | $53.65M | $42.84M | $38.65M | $45.93M |
| Long-term Debt | $51.66M | $51.62M | $51.57M | $51.52M | $51.50M | $51.47M | $51.44M | $51.40M | $51.37M | $51.34M |
| Total Liabilities | $139.40M | $142.21M | $131.26M | $127.26M | $130.22M | $131.80M | $132.92M | $122.57M | $118.85M | $123.97M |
| Stockholders' Equity | $347.67M | $365.87M | $380.28M | $385.80M | $389.16M | $402.22M | $241.22M | $251.78M | $264.05M | $280.75M |
| Retained Earnings | ($673.20M) | ($641.56M) | ($611.71M) | ($590.30M) | ($570.72M) | ($545.99M) | ($527.13M) | ($506.15M) | ($480.53M) | ($454.57M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($38.13M) | - | - | - | ($16.98M) | - | - | - | ($32.29M) | - |
| Investing Cash Flow | ($2.91M) | - | - | - | ($1.84M) | - | - | - | ($1.95M) | - |
| Financing Cash Flow | $222.0K | - | - | - | $1.30M | - | - | - | $2.59M | - |
| CapEx | $2.91M | - | - | - | $1.84M | - | - | - | $1.95M | - |
| Free Cash Flow | ($41.04M) | - | - | - | ($18.82M) | - | - | - | ($34.23M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 64.9% | - | 64.8% | 65.4% | 63.9% | - | 63.2% | 59.0% | 56.2% | - |
| Operating margin | -39.2% | - | -27.8% | -28.0% | -39.7% | - | -38.4% | -50.3% | -62.1% | - |
| EBITDA margin | -37.1% | - | - | - | -37.5% | - | - | - | -59.4% | - |
| Net margin | -38.1% | - | -25.7% | -24.7% | -35.8% | - | -35.9% | -48.0% | -58.3% | - |
| Free cash flow margin | -49.4% | - | - | - | -27.2% | - | - | - | -76.9% | - |
| FCF / Net income | 1.30 | - | - | - | 0.76 | - | - | - | 1.32 | - |
| R&D / Revenue | 25.8% | - | 21.8% | 22.3% | 23.7% | - | 28.5% | 32.8% | 29.4% | - |
| SG&A / Revenue | 78.3% | - | 70.8% | 71.1% | 79.8% | - | 73.1% | 76.5% | 88.9% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -6.5% | - | -4.2% | -3.8% | -4.8% | - | -5.6% | -6.8% | -6.8% | - |
| Return on equity | -9.1% | - | -5.6% | -5.1% | -6.4% | - | -8.7% | -10.2% | -9.8% | - |
| Return on invested capital | -6.5% | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.73 | 6.85 | 8.44 | 9.21 | 8.95 | 9.07 | 6.02 | 7.51 | 8.52 | 7.63 |
| Quick ratio | 5.51 | 5.77 | 7.20 | 7.86 | 7.75 | 8.01 | 5.07 | 6.49 | 7.44 | 6.77 |
| Cash ratio | 3.86 | 4.35 | 5.46 | 6.09 | 6.07 | 6.28 | 3.67 | 5.00 | 5.84 | 5.60 |
| Leverage | ||||||||||
| Debt / Equity | 0.15 | 0.14 | 0.14 | 0.13 | 0.13 | 0.13 | 0.21 | 0.20 | 0.19 | 0.18 |
| Debt / Assets | 0.11 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.14 | 0.14 | 0.13 | 0.13 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -39.9x | - | -25.2x | -24.8x | -26.3x | - | -22.0x | -27.8x | -26.5x | - |
| Equity multiplier | 1.40 | 1.39 | 1.35 | 1.33 | 1.33 | 1.33 | 1.55 | 1.49 | 1.45 | 1.44 |
| Liabilities / Assets | 0.29 | 0.28 | 0.26 | 0.25 | 0.25 | 0.25 | 0.36 | 0.33 | 0.31 | 0.31 |
| Efficiency | ||||||||||
| Asset turnover | 0.17 | - | 0.16 | 0.15 | 0.13 | - | 0.16 | 0.14 | 0.12 | - |
| Inventory turnover | 0.38 | - | 0.44 | 0.41 | 0.40 | - | 0.42 | 0.50 | 0.47 | - |
| Days sales outstanding | 423d | - | 370d | 373d | 418d | - | 432d | 403d | 460d | - |
| Days inventory outstanding | 970d | - | 830d | 892d | 910d | - | 865d | 732d | 779d | - |
| Days payable outstanding | 236d | - | 138d | 157d | 216d | - | 257d | 166d | 189d | - |
| Cash conversion cycle | 1157d | - | 1062d | 1108d | 1112d | - | 1040d | 969d | 1050d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 4.1x | - | 5.2x | 8.3x | 8.2x | - | 17.3x | 12.5x | 9.5x | - |
| P / S | 17.0x | - | 23.9x | 40.3x | 46.3x | - | 71.4x | 59.1x | 56.6x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 20.2% | - | 42.8% | 48.4% | 55.3% | - | 66.3% | 61.2% | 82.5% | - |
| Revenue CAGR (3y) | 50.5% | - | 60.0% | 110.6% | 69.5% | - | 202.6% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 22.2% | - | 46.3% | 64.4% | 76.4% | - | 95.6% | 70.8% | 100.4% | - |
| Operating income growth (YoY) | -18.8% | - | -3.4% | 17.3% | 0.8% | - | 12.4% | -4.7% | 2.6% | - |
| Net income growth (YoY) | -27.9% | - | -2.1% | 23.6% | 4.7% | - | 14.8% | -1.3% | 8.9% | - |
| EPS growth (YoY) | -24.4% | - | 5.0% | 30.0% | 11.8% | - | 21.6% | 10.7% | 19.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -118.1% | - | - | - | 45.0% | - | - | - | 17.0% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -10.7% | -9.0% | 57.6% | 53.2% | 47.4% | 43.3% | -19.4% | 61.5% | 52.5% | 42.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$270.38M totalHand Pieces And Other Consumables$159.67M · 59.1%
System Sales And Rentals$93.00M · 34.4%
Service Revenue$17.71M · 6.5%
Geographic
$308.05M totalUS$270.38M · 87.8%
Non Us$37.68M · 12.2%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing PROCEPT BioRobotics Corp against the 5 most active filers in the same SIC group.